Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 3Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Penile Neoplasms 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

fludarabine 5Cyclophosphamide 5aldesleukin 4fludarabine phosphate 2entinostat 2aflibercept 2Radiotherapy 2Adoptive Transfer 2rocakinogene sifuplasmid 1pembrolizumab 1oncogene protein E7, Human papillomavirus type 16 1durvalumab 1bintrafusp alfa protein, human 1Vorinostat 1VGX-3100 1Ritonavir 1Quality of Life 1Psychiatric Rehabilitation 1Platinum 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1MEDI0457 1Isotretinoin 1Interleukin-2 1Interferon-alpha 1Indinavir 1Immunotherapy 1Immunohistochemistry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Penile Neoplasms × BAY 1895344 × Gynecologic × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡